4.6 Article

Rare CNVs provide novel insights into the molecular basis of GH and IGF-1 insensitivity

Journal

EUROPEAN JOURNAL OF ENDOCRINOLOGY
Volume 183, Issue 6, Pages 581-595

Publisher

BIOSCIENTIFICA LTD
DOI: 10.1530/EJE-20-0474

Keywords

-

Funding

  1. Barts Charity Large Project Grant [MRC0161]
  2. 2018 European Society for Paediatric Endocrinology (ESPE) Research Fellowship

Ask authors/readers for more resources

Objective: Copy number variation (CNV) has been associated with idiopathic short stature, small for gestational age and Silver-Russell syndrome (SRS). It has not been extensively investigated in growth hormone insensitivity (GHI; short stature, IGF-1 deficiency and normal/high GH) or previously in IGF-1 insensitivity (short stature, high/normal GH and IGF-1). Design and methods: Array comparative genomic hybridisation was performed with similar to 60 000 probe oligonucleotide array in GHI (n = 53) and IGF- 1 insensitivity (n = 10) subjects. Published literature, mouse models, DECIPHER CNV tracks, growth associated GWAS loci and pathway enrichment anal yses were used to identify key biological pathways/ novel candidate growth genes within the CNV regions. Results: Both cohorts were enriched for class 3-5 CNVs (7/53 ( 13%) GHI a nd 3/10 ( 30%) IGF-1 insensitivity patients). Interestingly, 6/10 (60%) CNV subjects had diagnostic/associated clinical features of SRS. 5/10 subjects (50%) had CNVs previously reported in suspected SRS: 1q21 (n = 2), 12q14 (n = 1) deletions and Xp22 (n = 1), Xq26 (n = 1) duplications. A novel 15q11 deletion, previously associated with growth failure but not SRS/GHI was identified. Bioinformatic analysis identified 45 novel candidate growth genes, 15 being associated with growth in GWAS. The WNT canonical pathway was enriched in the GHI cohort and CLOCK was identified as an upstream regulator in the IGF- 1 insensitiv ity cohorts. Conclusions: Our cohort was enriched for low frequency CNVs. Our study emphasises the importance of CNV testing in GHI and IGF-1 insensitivity patients, particularly GHI subjects with SRS features. Functional experimental evidence is now required to validate the novel candidate growth genes, inte ractions and biological pathways identified.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available